Get the latest news, insights, and market updates on TWST (Twist Bioscience Corporation). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Twist Bioscience Q1 2026 Earnings Call Transcript
With me on the call today are Dr. Emily Leproust, CEO and co-founder of Twist Bioscience Corporation, Adam Laponis, CFO of Twist Bioscience Corporation, and Dr. Patrick Finn, President and COO of Twist Bioscience Corporation. Today, we will discuss our business progress, financial and operational performance, as well as growth opportunities. Feb 2, 2026 - $TWST
Twist Bioscience (TWST) Reports Q1 Loss, Misses Revenue Estimates
Twist Bioscience (TWST) delivered earnings and revenue surprises of -5.26% and -0.05%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock? Feb 2, 2026 - $TWST
Twist Bioscience: Fiscal Q1 Earnings Snapshot
TWST) on Monday reported a loss of $30.5 million in its fiscal first quarter. On a per-share basis, the South San Francisco, California-based company said it had a loss of 50 cents. The maker of synthetic DNA for the biotechnology industry posted revenue of $103.7 million in the period. Feb 2, 2026 - $TWST
Twist Bioscience Announces Fiscal 2026 First Quarter Financial Results
SOUTH SAN FRANCISCO, Calif., February 02, 2026--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the first quarter fiscal 2026 ended December 31, 2025. Feb 2, 2026 - $TWST
Antibody Discovery Market to Hit USD 35.35 Billion by 2035, Driven by AI and Technology Innovations
The global antibody discovery market, valued at USD 11.15 billion in 2025, is expected to surge to USD 35.35 billion by 2035, growing at a CAGR of 12.23%. This growth is fueled by advancements in engineering technologies, automation, and AI, benefiting the development of fully human and humanized antibodies, which enhance therapeutic attributes. Major technologies like phage display and glycoengineering propel this trend. AI and machine learning are streamlining discovery, while innovations such Jan 22, 2026 - $TWST
Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue
SOUTH SAN FRANCISCO, Calif., January 12, 2026--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced preliminary, unaudited revenue for the first quarter of fiscal 2026 ended December 31, 2025. Jan 12, 2026 - $TWST
Twist Bioscience (TWST) Valuation Check After TD Cowen Buy Rating And Raised Outlook
Twist Bioscience (TWST) is back on investor watchlists after TD Cowen’s Brendan Smith reaffirmed his positive stance on the company and significantly raised his outlook, accompanied by broadly supportive views from other brokers. See our latest analysis for Twist Bioscience. At a share price of $35.32, Twist Bioscience has seen short term momentum pick up, with a 90 day share price return of 13.24%. Over the same period, the 1 year total shareholder return shows an 18.99% decline, while the 3... Jan 11, 2026 - $TWST
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple